Takeaways: Exdensur positions GSK as the first biologic in Canada with twice-yearly dosing for severe eosinophilic asthma, a major convenience advantage over existing IL‑4/5...
Takeaways: The positive recommendation from CDA-AMC, backed by Phase III BE HEARD I and II trials, should accelerate payer negotiations and improve access for patients with chronic, pa...
Takeaways: Gazyva’s reimbursement recommendation is a clear commercial win for Roche because it opens the door to public coverage in a high-need, specialty autoimmune market...
Takeaways: Bosaya and Vevzuo, layered on top of other recent denosumab biosimilar launches, should accelerate formulary switches and tender competition, strengthen Biocon’s credi...
Takeaways: Health Canada has authorized PrUpgolyv (golimumab injection), giving Canada its first Simponi biosimilar and further extending JAMP Pharma’s BioJAMP immunolo...
Takeaways: AstraZeneca deepens its Saphnelo franchise in Canada by adding a self‑administered SC autoinjector on top of IV, improving convenience and persistency in a chronic, mostly f...
